Abstract:Background: The global burden of non-alcoholic fatty liver disease (NAFLD) is growing, but its subsequent health consequences have not been thoroughly examined. We performed phenome-wide Mendelian randomization and disease-trajectory analyses to comprehensively assess the health outcomes of NAFLD.Methods: PheWAS analyses were conducted to map the associations of NAFLD with a broad range of phenotypes among 475,554 European in UK Biobank. Disease-trajectory and comorbidity analyses were applied to visualize the sequential patterns of multiple comorbidities related to the occurrence of NAFLD. The associations jointly verified by observational and polygenic PheWAS analyses were further replicated by two-sample MR analysis using data from the FinnGen study and international consortia.Findings: PheWAS analyses including 1,172 disease outcomes revealed the associations of NAFLD diagnosis (n=9,035) with intrahepatic (e.g., cirrhosis, liver abscess and liver cancer) and extrahepatic diseases, including circulatory diseases (i.e., various cardiac diseases, hypertension and cerebrovascular diseases), metabolic diseases (i.e., hyperlipidemia and diabetes mellitus), genitourinary system diseases (i.e., renal failure), neurological disorders (i.e., dementias and Alzheimer's disease), gastrointestinal diseases (i.e., gastritis, duodenitis and ulcerative colitis, stomach cancer and other malignant digestive neoplasms) and hematologic diseases (i.e., iron deficiency anemia and thrombocytopenia). Disease-trajectory and comorbidity network analyses identified 3 major extrahepatic comorbidities clusters related to NAFLD, mainly in cardiovascular, metabolic, and inflammatory diseases. Two-sample MR analyses supported the causal associations between NAFLD and the risk of several intrahepatic disorders, metabolic diseases, cardio-cerebro-vascular disease and ascites, but found no associations with neurological diseases (i.e., dementia).Interpretation: A prior diagnosis of NAFLD was associated with an increased risk of various extrahepatic diseases of circulatory, metabolic, genitourinary, gastrointestinal and possibly neurological systems. Three major sequential patterns of comorbidities related to NAFLD were identified, mainly in cardiovascular, metabolic and inflammatory diseases, contributing to development of combination interventions targeting distinct pathways for the health promotion among NAFLD patients.Funding: XL: the Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001) and the National Nature Science Foundation of China (N0. 82204019); SCL: the Swedish Heart-Lung Foundation (Hjärt-Lungfonden, 20210351), the Swedish Research Council (Vetenskapsrådet, 2019-00977), and the Swedish Cancer Society (Cancerfonden).Declaration of Interest: All authors report no potential conflicts of interest.Ethical Approval: Ethical approval was granted by the UK Biobank by the North West-Haydock Research Ethics Committee (REC reference: 16/NW/0274).

Clinical manifestations, healthcare resource utilization, and costs among patients with long-chain fatty acid oxidation disorders: a retrospective claims database analysis

Major clinical events and healthcare resource use among patients with long-chain fatty acid oxidation disorders in the United States: Results from LC-FAOD odyssey program

Understanding patient, caregiver, and healthcare provider perspectives of the management of long-chain fatty acid oxidation disorders

A Comprehensive LOVD Database for Fatty Acid Oxidation Disorders in Chinese Populations

Unique plasma metabolomic signatures of individuals with inherited disorders of long-chain fatty acid oxidation

A panel of free fatty acid ratios to predict the development of metabolic abnormalities in healthy obese individuals

Multisystem Health Comorbidity Networks of Nonalcoholic Fatty Liver Disease: Phenome-Wide Mendelian Randomization and Disease-Trajectory Analyses

Subclinical effects of long-chain fatty acid β-oxidation deficiency on the adult heart: A case-control magnetic resonance study

Changes in Clinical Manifestations Due to AFLD Retyping Based on the New MAFLD Criteria: An Observational Study Based on the National Inpatient Sample Database

Impact of chronic liver disease on outcomes of hospitalized patients with COVID‐19: A multicentre United States experience

Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA

Charting the COVID Long Haul Experience -- A Longitudinal Exploration of Symptoms, Activity, and Clinical Adherence

Healthcare utilisation of 282,080 individuals with long COVID over two years: a multiple matched control, longitudinal cohort analysis

Long-term monitoring of fatty acid oxidation defects: results from a MetabERN survey

Electronic Medical Records for Discovery Research in Nonalcoholic Fatty Liver Disease

COVID-19 and Fatty Liver Disorders

Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency in Chinese Patients: Eight Case Reports, Including One Case of Prenatal Diagnosis

Fatty Acid Beta-Oxidation Disorders: A Brief Review

Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients

Triheptanoin in patients with long-chain fatty acid oxidation disorders: clinical experience in Italy

Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19